1. Home
  2. BOLD vs PRE Comparison

BOLD vs PRE Comparison

Compare BOLD & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • PRE
  • Stock Information
  • Founded
  • BOLD 2018
  • PRE 2014
  • Country
  • BOLD United States
  • PRE Hong Kong
  • Employees
  • BOLD N/A
  • PRE N/A
  • Industry
  • BOLD
  • PRE Biotechnology: Laboratory Analytical Instruments
  • Sector
  • BOLD
  • PRE Industrials
  • Exchange
  • BOLD Nasdaq
  • PRE Nasdaq
  • Market Cap
  • BOLD 60.4M
  • PRE 60.2M
  • IPO Year
  • BOLD 2024
  • PRE N/A
  • Fundamental
  • Price
  • BOLD $2.35
  • PRE $4.42
  • Analyst Decision
  • BOLD Strong Buy
  • PRE Buy
  • Analyst Count
  • BOLD 3
  • PRE 1
  • Target Price
  • BOLD $23.00
  • PRE $9.00
  • AVG Volume (30 Days)
  • BOLD 84.8K
  • PRE 6.3K
  • Earning Date
  • BOLD 11-07-2024
  • PRE 12-03-2024
  • Dividend Yield
  • BOLD N/A
  • PRE N/A
  • EPS Growth
  • BOLD N/A
  • PRE N/A
  • EPS
  • BOLD N/A
  • PRE N/A
  • Revenue
  • BOLD N/A
  • PRE $22,662,330.00
  • Revenue This Year
  • BOLD N/A
  • PRE $64.44
  • Revenue Next Year
  • BOLD N/A
  • PRE $154.24
  • P/E Ratio
  • BOLD N/A
  • PRE N/A
  • Revenue Growth
  • BOLD N/A
  • PRE N/A
  • 52 Week Low
  • BOLD $2.33
  • PRE $2.85
  • 52 Week High
  • BOLD $15.24
  • PRE $7.84
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • PRE 46.30
  • Support Level
  • BOLD N/A
  • PRE $4.40
  • Resistance Level
  • BOLD N/A
  • PRE $4.85
  • Average True Range (ATR)
  • BOLD 0.00
  • PRE 0.23
  • MACD
  • BOLD 0.00
  • PRE -0.01
  • Stochastic Oscillator
  • BOLD 0.00
  • PRE 45.69

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About PRE Prenetics Global Limited

Prenetics Global Ltd is a health sciences company, that is dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.

Share on Social Networks: